MKC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
McCormick & Company Inc (MKC) is not a strong buy at the moment for a beginner, long-term investor. While the stock is oversold (RSI at 14.525) and has potential for recovery, the technical indicators are bearish, and there are significant headwinds such as rising input costs and mixed consumption trends. Additionally, the company's financial performance shows modest growth, but gross margin erosion and uncertain market conditions make it less appealing for immediate investment. A 'hold' action is recommended until more clarity emerges regarding the potential Unilever deal and the company's ability to navigate cost pressures.
The technical indicators for MKC are bearish. The MACD histogram is negative (-0.767) but contracting, indicating a potential slowing of the downtrend. The RSI is at 14.525, signaling the stock is oversold. However, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level (S1: 51.987). Key resistance levels are at R1: 57.908 and R2: 59.737, suggesting limited upside in the short term.
Potential acquisition of Unilever's food business, which could enhance McCormick's market position and competitiveness in the global seasoning market.
Modest revenue and net income growth in Q4 2025, with revenue up 2.91% YoY and net income up 5.30% YoY.
Rising input costs due to geopolitical tensions (Iran War) and limited pricing power.
Gross margin erosion (-2.94% YoY in Q4 2025).
Analysts have lowered price targets and earnings estimates, reflecting cost pressures and mixed consumption trends.
No significant insider or hedge fund trading activity to indicate confidence in the stock.
In Q4 2025, McCormick reported revenue of $1.85 billion (up 2.91% YoY), net income of $226.6 million (up 5.30% YoY), and EPS of $0.84 (up 5.00% YoY). However, gross margin dropped to 38.99% (-2.94% YoY), indicating cost pressures.
Analysts have a mixed view on MKC. While some maintain Buy or Overweight ratings, price targets have been lowered across the board (e.g., TD Cowen to $64, JPMorgan to $67, UBS to $59). Analysts cite rising costs, mixed consumption trends, and potential execution risks related to the Unilever deal as key concerns.
